Best Stocks Under $2.00 for 2021

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. Stocks continue to hit new all-time highs and the price-to-earnings ratios of most S&P 500 companies look very expensive. Many investors are having trouble finding low-priced stocks that haven't already appreciated greatly during the last decade. It's hard to find a good deal on Wall Street right now when even small S&P 500 companies are trading at market caps above $1 billion.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 25 times their annual earnings. While the stock market has become more expensive as a whole, there are still a handful of undervalued stocks that are trading at less than $2.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $2.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these comapnies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks and bitcoin stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $2.00 or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.


CES Energy Solutions logo

#1 - CES Energy Solutions

OTCMKTS:CESDF
Stock Price: $1.55
Average Trading Volume: 31,674 shares
Consensus Rating: Buy (6 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.52 (62.6% Upside)
CES Energy Solutions Corp., together with its subsidiaries, provides consumable chemical solutions throughout the life-cycle of the oilfield. It provides solutions at the drill-bit, at the point of completion and stimulation, at the wellhead and pump-jack, and through to the pipeline and midstream market. The company's solutions include corrosion inhibitors, demulsifiers, H2S scavengers, paraffin control products, surfactants, scale inhibitors, biocides, and other specialty products. It also designs and implements drilling fluid systems and completion solutions for oil and gas producers; and designs and manufactures production and specialty chemicals for use in the oil and natural gas production markets, the stimulation and fracturing markets, and the pipeline and midstream markets. In addition, the company provides environmental consulting, water management services, and drilling fluids waste disposal services primarily to oil and gas producers; and operates trucks and trailers to transport products in the oil and gas industry. It serves oil and natural gas industry, including multinational producers, intermediate oil and natural gas operators, independent juniors, and joint ventures, as well as pipeline and mid-stream markets in western Canada and the United States. The company was formerly known as Canadian Energy Services & Technology Corp. and changed its name to CES Energy Solutions Corp. in June 2017. CES Energy Solutions Corp. was incorporated in 1986 and is headquartered in Calgary, Canada.
Serco Group logo

#2 - Serco Group

OTCMKTS:SECCF
Stock Price: $1.84 (-$0.01)
Average Trading Volume: 6,350 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: N/A
Serco Group plc provides public services in the United Kingdom, Europe, North America, the Asia Pacific, and the Middle East. The company offers base and operational support engineering, and management and information, as well as nuclear, space, and maritime services for the defense sector; and custodial, immigration detention, and detainee transport and monitoring services for the justice and immigration sectors. It also provides rail, ferry, and cycle operations; road traffic management; and air traffic control services to the transportation sector, as well as integrated facilities management, pathology and non-clinical support, and patient administration and contact services for the health sector. In addition, the company offers citizen services, including contact centers and case management; middle, back office, and IT; and employment and skills services. The company serves the United Kingdom and Canadian governments, devolved authorities, and other public sector customers; and federal and civilian agencies, and various state and municipal governments. Serco Group plc was founded in 1929 and is based in Hook, the United Kingdom.
Quisitive Technology Solutions logo

#3 - Quisitive Technology Solutions

OTCMKTS:QUISF
Stock Price: $1.30
Average Trading Volume: 53,912 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.05 (57.7% Upside)
Quisitive Technology Solutions, Inc., through its subsidiaries, provides Microsoft solutions primarily in North America. The company offers Microsoft cloud solutions, including Microsoft Azure, Microsoft Dynamics business applications, and Microsoft O365; CRG emPerform, an employee performance management software for small and medium sized business; and LedgerPay, Microsoft cloud-based payment processing and data insights product platform, as well as business solutions from other technology partners that are related to the Microsoft platform. It also provides Microsoft cloud assessment, migration and implementation, and activation services; cloud solutions services; and managed services, such as system administration and operations, and monitoring, as well as application maintenance, configurations, and upgrading. In addition, the company offers artificial intelligence, big data, block chain development, and Internet of Things solutions. Additionally, the company offers cloud solutions for healthcare, oil and gas, and supply chain and manufacturing industries. Quisitive Technology Solutions, Inc. has a collaboration with Inform Diagnostics. The company was formerly known as Nebo capital corp. and changed its name to Quisitive Technology Solutions, Inc. in August 2018. Quisitive Technology Solutions, Inc. is based in Toronto, Canada.
Sabina Gold & Silver logo

#4 - Sabina Gold & Silver

OTCMKTS:SGSVF
Stock Price: $1.38 (-$0.03)
Average Trading Volume: 525,394 shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $3.92 (183.4% Upside)
Sabina Gold & Silver Corp., a precious metals company, engages in the exploration and development of mineral resource properties in Canada. The company primarily explores for gold and silver deposit. Its flagship projects include Back River gold project comprising Goose, George, Boulder, Boot, and Del properties, as well as the port facility at Bathurst Inlet that covers an area of approximately 564 square kilometers located in Nunavut, Canada; and silver royalty on the Hackett River project that covers an area of approximately 10,637 hectares, located in Nunavut, Canada. The company was formerly known as Sabina Silver Corporation and changed its name to Sabina Gold & Silver Corp. in October 2009. Sabina Gold & Silver Corp. was incorporated in 1966 and is headquartered in Vancouver, Canada.
Motus GI logo

#5 - Motus GI

NASDAQ:MOTS
Stock Price: $1.04 (-$0.03)
PE Ratio: -1.60
Market Cap: $48.65 million
Average Trading Volume: 3.91 million shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.26 (117.5% Upside)
Motus GI Holdings, Inc., a medical technology company, provides endoscopy solutions that enhance clinical outcomes and the cost-efficiency associated with colonoscopy in the United States and Israel. Its flagship product is the Pure-Vu system, a medical device to facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The company was incorporated in 2016 and is based in Fort Lauderdale, Florida.
9 Meters Biopharma logo

#6 - 9 Meters Biopharma

NASDAQ:NMTR
Stock Price: $1.34 (-$0.09)
PE Ratio: -2.31
Market Cap: $336.84 million
Average Trading Volume: 7.71 million shares
Consensus Rating: Buy (9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $4.71 (251.8% Upside)
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on patients with rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease, as well as for undisclosed rare diseases and/or unmet needs. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease; and NM-002, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that is in Phase 2 clinical trial to treat SBS. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. 9 Meters Biopharma, Inc. has a collaboration with the Duke Clinical Research Institute to support the clinical development of NM-002. The company is headquartered in Raleigh, North Carolina.
CohBar logo

#7 - CohBar

NASDAQ:CWBR
Stock Price: $1.37 (+$0.01)
PE Ratio: -4.57
Market Cap: $84.65 million
Average Trading Volume: 563,266 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.00 (265.0% Upside)
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, acute respiratory distress syndrome, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial-derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases, CB5064 analogs for COVID-19 associated ARDS, MBT5 analogs for CXCR4-related cancer and orphan diseases, and MBT3 analogs for cancer immunotherapy. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
Agile Therapeutics logo

#8 - Agile Therapeutics

NASDAQ:AGRX
Stock Price: $1.41 (-$0.04)
PE Ratio: -2.01
Market Cap: $124.45 million
Average Trading Volume: 1.31 million shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $7.25 (414.2% Upside)
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.
ADMA Biologics logo

#9 - ADMA Biologics

NASDAQ:ADMA
Stock Price: $1.72 (-$0.07)
PE Ratio: -2.21
Market Cap: $220.49 million
Average Trading Volume: 5.54 million shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $7.80 (353.5% Upside)
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
DURECT logo

#10 - DURECT

NASDAQ:DRRX
Stock Price: $1.70 (+$0.02)
PE Ratio: -170.00
Market Cap: $386.59 million
Average Trading Volume: 1.53 million shares
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.60 (288.2% Upside)
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Gilead Sciences, Inc. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
Tamarack Valley Energy logo

#11 - Tamarack Valley Energy

OTCMKTS:TNEYF
Stock Price: $1.97 (-$0.05)
Average Trading Volume: 37,879 shares
Consensus Rating: Buy (7 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $3.34 (69.5% Upside)
Tamarack Valley Energy Ltd. acquires, explores, develops, and produces crude oil, natural gas, and natural gas liquids in the Western Canadian sedimentary basin. It primarily holds interests in Alberta Cardium light oil plays in Wilson Creek/Alder Flats/Pembina, and Garrington and Lochend areas in Alberta; Viking light oil resource plays in Redwater in Alberta, as well as in the Veteran, Consort, and Esther area of southeast Alberta and North Hoosier, Milton, and Coleville area of southwest Saskatchewan; Barons and Banff light oil plays located in the Penny area of Southern Alberta; and heavy oil properties. The company was formerly known as Tango Energy Inc. and changed its name to Tamarack Valley Energy Ltd. in June 2010. Tamarack Valley Energy Ltd. is headquartered in Calgary, Canada.
Western Forest Products logo

#12 - Western Forest Products

OTCMKTS:WFSTF
Stock Price: $1.58 (+$0.01)
Average Trading Volume: 59,811 shares
Consensus Rating: Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.58 (63.3% Upside)
Western Forest Products Inc. operates as an integrated softwood forest products company. It is involved in the timber harvesting, sawmilling logs into specialty lumber, value-added lumber remanufacturing, and lumber purchasing and wholesaling. The company offers various products for outdoor living space, such as structures, decking, landscaping, and fencing; home components, including appearance and structural timbers, Japanese housing, and framing, as well as siding, paneling, trim, and soffits; and furniture, moldings, and decorative purpose, as well as doors, windows, and stair components. It also provides its products for cross arms and transmission arms, mat stock, bridges, docks and railway ties, and packaging and crating; and architectural fixtures, lam stock, and timbers. The company sells its products in Canada, the United States, China, Japan, Europe, and internationally. Western Forest Products Inc. was incorporated in 2004 and is headquartered in Vancouver, Canada.
Roxgold logo

#13 - Roxgold

OTCMKTS:ROGFF
Stock Price: $1.60 (-$0.01)
Average Trading Volume: 104,109 shares
Consensus Rating: Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.57 (60.6% Upside)
Roxgold Inc., a gold mining company, engages in the exploration, evaluation, and development of mineral properties. It holds interest in the Yaramoko gold project located in the Houndé greenstone belt of Burkina Faso, West Africa; and 100% interest in the Séguéla gold project that includes 11 exploration permits situated in Côte d'Ivoire. The company is headquartered in Toronto, Canada.
Allena Pharmaceuticals logo

#14 - Allena Pharmaceuticals

NASDAQ:ALNA
Stock Price: $1.27 (-$0.03)
PE Ratio: -1.37
Market Cap: $73.27 million
Average Trading Volume: 1.53 million shares
Consensus Rating: Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $10.50 (726.8% Upside)
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and moderate to severe chronic kidney diseases. Allena Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Newton, Massachusetts.
T2 Biosystems logo

#15 - T2 Biosystems

NASDAQ:TTOO
Stock Price: $1.29 (-$0.01)
PE Ratio: -4.16
Market Cap: $193.64 million
Average Trading Volume: 9.12 million shares
Consensus Rating: Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.83 (119.4% Upside)
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance technology that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida Panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it provides T2Bacteria Panel, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2SARS-CoV-2 Panel, a COVID-19 molecular diagnostic test; and T2Resistance Panel for the early and sensitive detection of carbapenemase-resistance markers. Further, it develops T2Cauris Panel, a multi-drug resistant pathogen; and T2Lyme Panel for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Stagecoach Group logo

#16 - Stagecoach Group

OTCMKTS:SAGKF
Stock Price: $1.21
Market Cap: $693.74 million
Average Trading Volume: 1,821 shares
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: N/A
Stagecoach Group plc, together with its subsidiaries, provides public transportation services in the United Kingdom. It operates through three segments: UK Bus (Regional Operations), UK Bus (London), and UK Rail. The company offers bus, coach, rail, and tram services. It operates city buses primarily in Liverpool, Newcastle, Hull, Manchester, Oxford, Sheffield, Cambridge, and Exeter through a fleet of approximately 7,100 buses and coaches; inter-urban services linking major towns within its regional operating areas, as well as megabus.com, an inter-city coach service; and buses from 10 depots with a fleet of approximately 1,150 buses serving routes in and around east and south-east London. The company also operates Sheffield Supertram, a 28 km light rail network with three routes in the city of Sheffield. It serves individuals, local authorities, transport authorities, and the United Kingdom department for transport. The company was founded in 1980 and is headquartered in Perth, the United Kingdom.
Americas Silver logo

#17 - Americas Silver

NYSEAMERICAN:USAS
Stock Price: $1.57 (-$0.04)
PE Ratio: -1.69
Market Cap: $209.27 million
Average Trading Volume: 1.36 million shares
Consensus Rating: Buy (4 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $4.50 (186.6% Upside)
Americas Gold and Silver Corporation engages in the acquisition, evaluation, exploration, development, and operation of mineral properties. The company explores for silver, lead, zinc and copper. It principally owns 100% interests in the Cosalá Operations consisting of 67 mining concessions that cover approximately 19,385 hectares located in the state of Sinaloa, Mexico; and Galena Complex situated near the town of Wallace in the state of Idaho, the United States. The company was formerly known as Americas Silver Corporation and changed its name to Americas Gold and Silver Corporation in September 2019. Americas Gold and Silver Corporation was incorporated in 1998 and is headquartered in Toronto, Canada.
Aker Solutions ASA logo

#18 - Aker Solutions ASA

OTCMKTS:AKRTF
Stock Price: $1.93
Average Trading Volume: 4,629 shares
Consensus Rating: Buy (5 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: N/A
Aker Solutions ASA provides products, systems, and services to the oil and gas industry worldwide. It offers field planning, feasibility, and concept studies; floater designs; digital solutions; and deep-water risers. The company also provides engineering, project management, and procurement services, such as design of offshore oil and gas production facilities, and onshore receiving and processing facilities; jacket designs; subsea production systems; subsea trees; and control systems. In addition, it offers subsea wellheads engineering, manufacturing, installation, and life-of-field support services, including umbilical systems, subsea structures, tie-in systems, subsea compression and pump systems, subsea power distribution and processing systems, and intervention and workover systems; and lifecycle, hook-up and completion, maintenance, modification, decommissioning, asset integrity management, and yards and fabrication services. Aker Solutions ASA was founded in 1841 and is headquartered in Fornebu, Norway.
Yangarra Resources logo

#19 - Yangarra Resources

OTCMKTS:YGRAF
Stock Price: $1.13 (-$0.01)
Average Trading Volume: 22,714 shares
Consensus Rating: Buy (2 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $0.83 (-26.5% Upside)
Yangarra Resources Ltd., a junior oil and gas company, engages in the exploration, development, and production of oil and natural gas properties in Western Canada. As of March 4, 2021, it had proved plus probable reserves of 157.6 million barrels of oil equivalent. The company is headquartered in Calgary, Canada.
Taseko Mines logo

#20 - Taseko Mines

NYSEAMERICAN:TGB
Stock Price: $1.92 (-$0.03)
PE Ratio: 38.41
Market Cap: $543.72 million
Average Trading Volume: 3.01 million shares
P/E Ratio: 38.4
Consensus Rating: Buy (2 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.63 (36.7% Upside)
Taseko Mines Limited, a mining company, acquires, develops, and operates mineral properties. The company explores for copper, molybdenum, gold, niobium, and silver deposits. It holds 75% interest in the Gibraltar mine located in British Columbia. The company also holds 100% interest in Yellowhead copper project, the Aley niobium project, the Harmony Gold Project, and the New Prosperity gold and copper project located in British Columbia; and the Florence copper project located in Arizona. Taseko Mines Limited was incorporated in 1966 and is headquartered in Vancouver, Canada.

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.